Haptoglobin study in myasthenia gravis

Oliveira, Leonardo H. Mendonça; França, Marcondes C.; Nucci, Anamarli; Oliveira, De; Kimura, Eiichiro; Sonati, María de Fátima

doi:10.1590/s0004-282x2008000200017

Cited by 4 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Haptoglobin (Hp) is an acute phase protein . High levels of plasma or serum and its association with disease severity has been found in some autoimmune diseases like myasthenia gravis and rheumatoid arthritis . Cid et al .…”

Section: Discussionmentioning

confidence: 99%

Serum proteomic profiling in granumomatosis with polyangiitis using two-dimensional gel electrophoresis along with matrix assisted laser desorption ionization time of flight mass spectrometry

et al. 2014

View full text Add to dashboard Cite

Aim: The present study is a proteomic approach to find differentially expressed proteins in sera of limited and systemic subsets of active disease versus their remitting state in patients with granulomatosis with polyangiitis (GPA) and their correlation with disease activity.Methods: Eighteen patients with GPA in active as well as in remitting state and four healthy controls (HC) were included in the study. For proteomics analysis, two-dimensional gel electrophoresis along with matrix-assisted laser desorption ionization time-of-flight mass spectrometry were performed. A total of 14 gels were run from pooled patients' sera from active GPA and remission as well as pooled HC serum.Results: There was significant differential expression of proteins in limited versus systemic GPA and between active systemic versus remitting patients of systemic disease. We identified nine maximally differentially expressed and five proteins which were not detected in HC. Among nine proteins, one (Prolow density lipoprotein receptor-related protein 1) was downregulated and four proteins (haptoglobin Hp, Hp2, vitamin D binding protein, killer cell lectin-like receptor subfamily F member 2), were up-regulated in both limited and systemic active disease, two proteins like Ig gamma-4 chain C region protein and serum albumin were up-regulated in limited active GPA and two proteins, that is, cysteine rich secretory protein LCCL domain-containing 2 precursor and serine-threonine-protein kinase A-Raf were up-regulated in systemic active disease. Levels of interleukin-17 and vitamin-D binding protein (VDBP) by enzyme-linked immunosorbent assay could distinctly demarcate active disease versus remission. Conclusion:Our study provides potential protein markers of active disease versus remission in GPA.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum proteomic profiling in granumomatosis with polyangiitis using two-dimensional gel electrophoresis along with matrix assisted laser desorption ionization time of flight mass spectrometry

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This correlation could be explained by the presence of high levels of pro-inflammatory cytokines during active disease. To determine the Hp serum levels in patients with myasthenia can be useful to monitor the severity of the disease (Oliveira et al, 2008).…”

Section: Myasthenia Gravismentioning

confidence: 99%

Haptoglobin Function and Regulation in Autoimmune Diseases

Galicia¹,

Ceuppens²

2011

Acute Phase Proteins - Regulation and Functions of Acute Phase Proteins

View full text Add to dashboard Cite

“…A haptoglobina (HP) é uma á2-glicoproteína da fase inflamatória aguda sintetizada no fígado, que se liga a hemoglobina livre no plasma. É utilizada como marcador de diferentes doenças, uma vez que é possível detectar níveis aumentados desta proteína na fase aguda de processos inflamatórios ou infecciosos (OLIVEIRA et al, 2008).…”

Section: Diagnóstico Da Mgunclassified

Atualizações e Perspectivas na Miastenia gravis

BRANCO¹

2011

Rev. bras. ciênc. Saúde

View full text Add to dashboard Cite

This study aimed to a search the literature on myasthenia gravis (MG). Methodology: Literature search was conducted in the electronic databases PubMed, Science Direct, Scielo and Bireme, in the last ten years, and other articles that had extreme historical importance were also included. Results: MG is an autoimmune disease characterized by muscle weakness, whose pathogenesis is related to the destruction of neuromuscular transmission by different mechanisms, such as decreased nicotinic acetylcholine receptors, destruction of proteins involved in the neuromuscular formation or the activity of antibodies on a specific muscle protein kinase (MUSK). The current treatment of MG is based on the use of acetylcholinesterase inhibitors, corticosteroids, thymectomy, immunosuppressants, intravenous immunoglobulin and plasmapheresis. Early identification of MG and its precipitating factors make this disease more accessible to new treatment modalities such as monoclonal antibodies, prolactin, and tacrolimus crotamine. Conclusion: A better knowledge about molecular mechanisms has provided the development of new therapeutic options necessary to alleviate severe crises, leading to a proper prognosis. New findings may contribute to the quality of life of patients, resulting in remission of the disease and not just in relieving its symptoms. DESCRIPTORS Myasthenia Gravis. Acetylcholine. Combined Modality Therapy. Immune System. http://periodicos.ufpb.br/ojs2/index.php/rbcs

show abstract

Haptoglobin study in myasthenia gravis

Cited by 4 publications

References 17 publications

Serum proteomic profiling in granumomatosis with polyangiitis using two-dimensional gel electrophoresis along with matrix assisted laser desorption ionization time of flight mass spectrometry

Serum proteomic profiling in granumomatosis with polyangiitis using two-dimensional gel electrophoresis along with matrix assisted laser desorption ionization time of flight mass spectrometry

Haptoglobin Function and Regulation in Autoimmune Diseases

Atualizações e Perspectivas na Miastenia gravis

Contact Info

Product

Resources

About